Worldwide Pulmonary Arterial Hypertension Industry to 2026 - Advance Oral Drugs for Pulmonary Arterial Hypertension Present Opportunities
05 juil. 2021 04h28 HE
|
Research and Markets
Dublin, July 05, 2021 (GLOBE NEWSWIRE) -- The "Global Pulmonary Arterial Hypertension Market (2021-2026) by Drug Class, Route of Administration, Distribution Mode, Geography, Competitive Analysis...
Worldwide Pulmonary Arterial Hypertension Industry to 2025 - Featuring Gilead Sciences, United Therapeutics and Novartis International Among Others
20 janv. 2021 06h33 HE
|
Research and Markets
Dublin, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Pulmonary Arterial Hypertension (2020-2025) by Drug Class, Route of Administration, Distribution Mode, Geography, Competitive Analysis and the...
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2020: Increasing Awareness Regarding Available Treatment Alternatives to Drive Market Growth
01 déc. 2020 05h18 HE
|
Research and Markets
Dublin, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension (PAH) Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been...
DRGT Announces Hungarian Regulatory Authority Approval and Subsequent Initiation of a Phase 2 Trial of DRGT-119 in Patients With Chronic Anal Fissure
15 juil. 2019 09h00 HE
|
Druggability Technologies Holdings Ltd
BUDAPEST, Hungary, July 15, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced the start of a phase 2 randomized, double-blind, placebo-controlled trial to evaluate...